A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer

NCT01935453 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma
Liver Cancer
Pancreatic Cancer
Lung Cancer

Interventions

BIOLOGICAL: Recombinant hGM-CSF Herpes Simplex Virus Injection

Sponsor

OrienGene Biotechnology Ltd.

Collaborators

[object Object]
[object Object]